Lumen BioMedical is developing a wearable closed system designed to give patients and physicians a level of glaucoma management that does not exist today — continuous, intelligent, and responsive.
Glaucoma is the second leading cause of irreversible blindness worldwide. Despite decades of research, the standard of care leaves patients without the continuous visibility and responsive management their condition demands.
The moments that matter most in glaucoma are precisely the ones that current care cannot capture. Lumen BioMedical intends to change that.
Disease-relevant changes occur outside clinic hours. Standard care captures a single data point, not the continuous pattern that drives progression.
Daily self-administered drops are the primary intervention. In real-world practice, non-compliance is widespread and largely invisible to physicians.
Continuous monitoring transformed diabetes care. Lumen BioMedical intends to apply that same principle to glaucoma — sustained visibility, responsive management.
Lumen BioMedical is developing a wearable system designed to give physicians continuous clinical visibility and give patients responsive care, without surgery, without hospital visits, and without lifestyle change.
A wearable system that works continuously without requiring daily patient action, providing protection and care around the clock including during the hours when the disease is most active.
A connected clinical platform intended to provide treating physicians with continuous patient data and timely alerts, enabling proactive decisions without waiting for the next scheduled visit.
A platform designed to reduce the downstream burden of unmanaged glaucoma progression including vision loss, surgical intervention, and the long-term care costs that preventable blindness creates.
Decades of academic research have validated the scientific foundation. The barrier has never been the underlying science. It has been the regulatory, clinical, and manufacturing infrastructure to bring a solution to patients. That is the gap Lumen BioMedical intends to close.
Connect with usLumen BioMedical is developing a proprietary wearable system designed to be worn like a conventional contact lens while delivering a level of clinical management that no current device or therapy can provide.
Glaucoma is a disease that demands continuous attention, yet current care provides only episodic snapshots. The Lumen BioMedical system is being designed to provide uninterrupted clinical visibility throughout the day and night, capturing the data that drives disease management decisions and making it available to the treating physician in a format that enables timely, informed action.
The system will be designed for wear like a conventional contact lens, requiring no surgery, no implantation, and no hospitalization. Patients will carry on with daily life while the system works continuously.
Disease-relevant pressure changes occur outside clinic hours. The system will be designed to provide continuous measurement where episodic tonometry cannot reach.
Non-compliance with self-administered therapy is the leading predictor of disease progression in treated patients. The system will be designed to address this without requiring patient action.
Treating physicians currently have no mechanism to monitor patients between visits. The system will be designed to give clinicians continuous, actionable clinical data.
The Lumen BioMedical platform is intended to give treating physicians a level of clinical visibility that is not available through any existing tool — continuous patient data accessible via a connected physician platform, with the ability to act when patient status changes between visits.
The platform will be designed for integration with major electronic health record systems, so that patient data flows into the clinical workflow physicians already use.
A companion patient application will be designed to keep patients informed and engaged with their own management, without presenting clinical complexity beyond what is useful and safe for a patient audience.
A central design goal of the Lumen BioMedical system is to remove the patient compliance variable from glaucoma management. Rather than depending on daily patient action for therapeutic delivery, the system is intended to respond when management is needed — automatically, without requiring the patient to initiate anything.
This design approach draws directly from the precedent established in diabetes care, where closing the loop between monitoring and treatment produced a step change in patient outcomes. Lumen BioMedical intends to bring that same paradigm to glaucoma.
Closed-loop insulin delivery transformed Type 1 diabetes management by automating the monitoring-to-treatment response. Lumen BioMedical intends to apply the same principle to ocular disease management — a system that monitors continuously and responds when action is needed, without depending on patient memory or adherence.
The specific technology, materials, and mechanisms underlying the Lumen BioMedical platform are proprietary. Technical details are available to qualified partners and investors under a signed non-disclosure agreement.
The scientific foundation for a better approach to glaucoma management has been established by academic researchers around the world. What has been missing is an organization purpose-built to translate that foundation into a safe, regulated, and commercially viable solution for patients.
Glaucoma affects more than 57 million people worldwide and is projected to reach 112 million by 2040. It is the second leading cause of irreversible blindness globally, and it progresses silently. Patients typically lose significant peripheral vision before noticing any change.
The disease's progression is driven by pressure that fluctuates continuously, peaks when patients are away from clinical care, and responds inadequately to therapies that depend entirely on patient self-administration. No current non-surgical device or system addresses all three of these realities simultaneously.
Disease-relevant pressure changes occur outside clinic hours. Current care provides a data point where a continuous record is needed.
Non-compliance with self-administered therapy is the single largest predictor of progression in treated patients and is largely invisible to treating physicians.
Glaucoma carries documented disparities in both prevalence and care access across underserved populations. A wearable management system designed for autonomous management reduces the frequency of clinic attendance required for effective disease control.
What follows describes the principles and approach that will guide development — commitments made now, as foundational disciplines of the program.
Lumen BioMedical will establish its regulatory pathway and classification before committing any capital to engineering or prototype development. Every design decision will be made with the regulatory submission in mind, not retrofitted to it afterward.
The development program will be built from the outset around an ISO 13485 compliant quality management system. Design controls, document management, and risk management will be established from the first day of engineering activity, not added before submission.
Clinical advisors will shape device design inputs from the earliest stages of the program. The pivotal study design will be agreed with regulatory authorities before enrollment begins, ensuring the evidence generated is the evidence required for clearance and reimbursement.
Glaucoma carries well-documented disparities in both prevalence and care access. Lumen BioMedical's commercial model will incorporate community health center partnerships and patient accessibility programs as a founding commitment, not an afterthought added after launch.
Distribution through community health centers will be built into the commercial model as a parallel channel alongside academic and group-practice partners.
Patient assistance and affordability programs will be designed into the commercial launch plan, not introduced reactively.
Demographic and geographic uptake will be tracked as a standing commercial performance indicator from launch.
Lumen BioMedical is looking to connect with early-stage investors, experienced medtech advisors, glaucoma specialists, and strategic partners who share our long-term vision for transforming glaucoma care.
For NDA inquiries, partnership discussions, investor relations, and media requests.
We are looking to connect with fellowship-trained glaucoma specialists at academic medical centers who are interested in shaping the clinical direction of the Lumen BioMedical platform.
We invite conversations with investors aligned with long-horizon medical device development. A full investor brief is available under NDA.
We are looking to engage regulatory consultants with FDA combination product and ophthalmic device experience. A Regulatory Product Brief is available under NDA.
All discussions are subject to mutual confidentiality. We will send an NDA for signature before sharing any proprietary technical or financial documentation.